Pfizer Sees Once Daily Danuglipron In The “Reasonable Future”

Aug 02 2023

• By Jessica Merrill

Listen to this article

The obesity market offers big revenue potential but Pfizer’s oral GLP-1 candidate is currently dosed twice daily.

scale — Pfizer updated investors on its GLP-1 agonist for weight loss • Source: Shutterstock

Pfizer Inc. investors are closely watching the development of a mid-stage oral GLP-1 drug for type 2 diabetes and obesity given how lucrative the obesity market is expected to be. But if Pfizer does successfully develop danuglipron in late-stage clinical trials, the company would be entering a market dominated by experienced rivals Novo Nordisk A/S and Eli Lilly and Company.

Key Takeaways

Pfizer updated investors on the development of an oral GLP-1 agonist for obesity

The three companies are all working to bring oral GLP-1 drugs to market for obesity, with Novo Nordisk squarely in...

More from Alimentary/Metabolic

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership
Dec 05 2025
• By Jung Won Shin
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena
Dec 05 2025
• By Xu Hu
Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.